- Thermo Fisher Introduces Homologous Recombination Deficiency Score for Cancer Profiling Assay.
- Han AP.
- GenomeWeb. 2022 Nov 7.
- News
- Loss of Heterozygosity of BRCA1/2 as a Predictive Marker for Talazoparib Response.
- Mizrahi AG, Hamad H, Gugenheim A, Nisman B, Kuznetz A, David IB, Gelfend Y, Cohen S, Zick A, Sheva K, Nechushtan H, Peretz T, Meirovitz A.
- Anticancer Res. 2022 Nov;42(11):5257-5263. doi: 10.21873/anticanres.16032.
- PMID: 36288893
- PubMed abstract
- Source abstract
- Efficacy and safety of Gemogenovatucel-T (Vigil) immunotherapy for advanced ovarian carcinoma: A systematic review and meta-analysis of randomized controlled trials.
- Zhang Y, Zhang L, Zhao Y, Wang S, Feng L.
- Front Oncol. 2022 Oct 21;12:945867. doi: 10.3389/fonc.2022.945867.
- PMID: 36338747
- PubMed abstract
- Meta-Analysis
- Free PMC article
- Free Full Text
•• Review registration number: CRD42022300367: Efficacy and safety of Gemogenovatucel-T (Vigil) immunotherapy for advanced ovarian cancer: A systematic review and meta-analysis of randomized controlled trials. (PROSPERO register. Accessed 2022 Nov 7.)